Twist Bioscience Corp Cash and Equivalents

Quick Answer

Twist Bioscience Corp reported Cash and Equivalents of $183.05 million for fiscal year 2025.

Twist Bioscience Corp Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $183.05M -19.1%
2024 $226.32M -21.0%
2023 $286.47M -24.4%
2022 $378.69M -18.7%
2021 $465.83M +397.3%
2020 $93.67M +100.4%
2019 $46.73M -42.1%
2018 $80.76M +158.6%
2017 $31.23M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
December 31, 2025 $148.59M -32.9% -18.8%
September 30, 2025 $183.05M -19.1% -9.1%
June 30, 2025 $201.37M -15.8% -4.3%
March 31, 2025 $210.44M -13.5% -5.0%
December 31, 2024 $221.40M -16.8% -2.2%
September 30, 2024 $226.32M -21.0% -5.4%
June 30, 2024 $239.14M -22.2% -1.7%
March 31, 2024 $243.35M -22.8% -8.6%
  • Twist Bioscience Corp showed a decrease of -19.1% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2017–2025 period, Twist Bioscience Corp’s cash and equivalents has grown by 486.2% (from $31.23 million to $183.05 million).
  • The most recent figure is from Twist Bioscience Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 17, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment